Human Genome Epidemiology Literature Finder
|
Records 1 - 30 (of 276 Records) |
| Query Trace: Recurrence and EGFR[original query] |
|---|
| Prognostic factors for relapse-free survival in stage IB-IIIA primary lung adenocarcinoma by epidermal growth factor receptor mutation status. BMC cancer 2022 9 22 (1): 966. Isaka Tetsuya, Ito Hiroyuki, Yokose Tomoyuki, Saito Haruhiro, Adachi Hiroyuki, Murakami Kotaro, Miura Jun, Kikunishi Noritake, Rino Yasus |
| EGFR mutation prevalence, real-world treatment patterns, and outcomes among patients with resected, early-stage, non-small cell lung cancer in Canada. Lung cancer (Amsterdam, Netherlands) 2022 Sep 173 58-66. Sara Kuruvilla M, Liu Geoffrey, Syed Iqra, Gwadry-Sridhar Femida, Sheffield Brandon S, Sachdeva Robin, Pencz Alec, Zhan Luna, Hueniken Katrina, Patel Devalben, Balaratnam Karmugi, Khan Khaleeq, Grant Benjamin, Noy Shawna, Singh Karan, Liu Linda, Rakibuz-Zaman Muhammad, Moldaver Daniel, Kate Shanahan Mary, Cheema Parneet |
| Advances in the treatment of postoperative recurrence of non-small cell lung cancer and their impact on survival in Asian patients. The Journal of thoracic and cardiovascular surgery 2022 Aug . Hashimoto Kohei, Ariyasu Ryo, Ichinose Junji, Matsuura Yosuke, Nakao Masayuki, Amino Yoshiaki, Uchibori Ken, Kitazono Satoru, Yanagitani Noriko, Okumura Sakae, Nishio Makoto, Mun Mingy |
| Adjuvant chemotherapy in patients with recurrence after completely resected stage IB lung adenocarcinoma: Propensity-matched analysis in a cohort of 147 recurrences. Thoracic cancer 2022 Sep . Xu Fei, Chen Heng-Chi, Xu Haiyan, Li Junling, Hao Xuezhi, Xing Puyuan, Ying Jianming, Wang Y |
| Biological Difference between L858R and Exon 19 Deletion Contributes to Recurrence-Free Survival of Resected Non-Small Cell Lung Cancer. Oncology 2022 Sep . Masago Katsuhiro, Kuroda Hiroaki, Fujita Shiro, Sasaki Eiichi, Takahashi Yusuke, Shinohara Shuichi, Matsushita Hiroka |
| Prognostic factors in completely resected lymph-node-negative pulmonary adenocarcinoma. Translational cancer research 2022 Jul 11 (7): 2238-2248. Pakvisal Nussara, Chantranuwat Poonchavist, Vinayanuwattikun Chanida, Sitthideatphaiboon Piyada, Teerapakpinyo Chinachote, Shuangshoti Shanop, Benjacholamas Vichai, Pornpattanarak Nopporn, Sriuranpong Viro |
| Comprehensive analysis of mutational profile and prognostic significance of complex glandular pattern in lung adenocarcinoma. Translational lung cancer research 2022 Jul 11 (7): 1337-1347. Bai Jinsong, Deng Chaoqiang, Zheng Qiang, Li Di, Fu Fangqiu, Li Yuan, Zhang Yang, Chen Haiqu |
| The prognostic impact of lung adenocarcinoma predominance classification relating to pathological factors in lobectomy, the Japanese Joint Committee of Lung Cancer Registry Database in 2010. BMC cancer 2022 Aug 22 (1): 875. Ito Hiroyuki, Date Hiroshi, Shintani Yasushi, Miyaoka Etsuo, Nakanishi Ryoichi, Kadokura Mitsutaka, Endo Shunsuke, Chida Masayuki, Yoshino Ichiro, Suzuki Hidemi, |
| Genomic Profiling Reveals Novel Predictive Biomarkers for Chemo-Radiotherapy Efficacy and Thoracic Toxicity in Non-Small-Cell Lung Cancer. Frontiers in oncology 2022 12 928605. He Kewen, Zhang Shaotong, Pang Jiaohui, Yin Jiani C, Mu Dianbin, Wang Jun, Ge Hong, Ma Jie, Yang Zhe, Zheng Xiaoli, Dong Lihua, Zhang Junli, Chang Pengyu, Li Li, Tang Shanshan, Bao Hua, Wu Xue, Wang Xiaonan, Shao Yang, Yu Jinming, Yuan Shuang |
| Cluster analysis of deterioration sites after first-line epidermal growth factor receptor-tyrosine kinase inhibitor in epidermal growth factor receptor mutated non-small cell lung cancer. Contemporary oncology (Poznan, Poland) 2022 7 26 (2): 123-127. Okauchi Shinichiro, Miyazaki Kunihiko, Satoh Hiroa |
| Mutant-Allele Tumor Heterogeneity, a Favorable Biomarker to Assess Intra-Tumor Heterogeneity, in Advanced Lung Adenocarcinoma. Frontiers in oncology 2022 7 12 888951. Wu Xiaoxuan, Song Peng, Guo Lei, Ying Jianming, Li Wenb |
| Prognostic impact of pretreatment T790M mutation on outcomes for patients with resected, EGFR-mutated, non-small cell lung cancer. BMC cancer 2022 Jul 22 (1): 775. Matsumoto Yoshiya, Kawaguchi Tomoya, Watanabe Masaru, Isa Shun-Ichi, Ando Masahiko, Tamiya Akihiro, Kubo Akihito, Kitagawa Chiyoe, Yoshimoto Naoki, Koh Yasuhi |
| Epithelial TGF? engages growth-factor signalling to circumvent apoptosis and drive intestinal tumourigenesis with aggressive features. Nature communications 2022 12 13 (1): 7551. Flanagan Dustin J, Amirkhah Raheleh, Vincent David F, Gunduz Nuray, Gentaz Pauline, Cammareri Patrizia, McCooey Aoife J, McCorry Amy M B, Fisher Natalie C, Davis Hayley L, Ridgway Rachel A, Lohuis Jeroen, Leach Joshua D G, Jackstadt Rene, Gilroy Kathryn, Mariella Elisa, Nixon Colin, Clark William, Hedley Ann, Markert Elke K, Strathdee Douglas, Bartholin Laurent, Redmond Keara L, Kerr Emma M, Longley Daniel B, Ginty Fiona, Cho Sanghee, Coleman Helen G, Loughrey Maurice B, Bardelli Alberto, Maughan Timothy S, Campbell Andrew D, Lawler Mark, Leedham Simon J, Barry Simon T, Inman Gareth J, van Rheenen Jacco, Dunne Philip D, Sansom Owen |
| PD-L1 Expression is not a Predictive Factor for Recurrence in Resected Non-small Cell Lung Cancer. Lung 2022 12 201 (1): 95-101. Motono Nozomu, Mizoguchi Takaki, Ishikawa Masahito, Iwai Shun, Iijima Yoshihito, Uramoto Hideta |
| A prognostic risk model for glioma patients by systematic evaluation of genomic variations. iScience 2022 12 25 (12): 105681. Zhang Baifeng, Wan Weiqing, Li Zibo, Gao Zhixian, Ji Nan, Xie Jian, Wang Junmei, Wang Bin, Lai-Wan Kwong Dora, Guan Xinyuan, Gao Shengjie, Zhao Yuanli, Lu Youyong, Zhang Liwei, Rodland Karin D, Tsang Shirley |
| The Effect of Gefitinib on Treatment Necessity and Prognosis of NSCLC Patients with Early EGFR Mutations. Contrast media & molecular imaging 2022 10 2022 2228744. Song Ruiqiang, Cheng Yanbo, Zheng Tian |
| Prognostic biomarkers correlated with immune infiltration in non-small cell lung cancer. FEBS open bio 2022 Oct . Xu Fei, Cui Wen-Qiang, Liu Cun, Feng Fubin, Liu Ruijuan, Zhang Jingtao, Sun Chang-Ga |
| EGFR Mutation-Positive Unresectable Stage III Non-Squamous Lung Cancer is Associated with a High Incidence of Brain Metastasis. Cancer research and treatment 2022 Oct . Kim Hongsik, Park Sehhoon, Jung Hyun Ae, Sun Jong-Mu, Lee Se-Hoon, Ahn Jin Seok, Ahn Myung- |
| Investigation of EGFR and ALK mutation frequency and treatment results in advanced non-small cell lung cancer. Journal of cancer research and therapeutics 2023 5 19 (Supplement): S183-S190. Berna Komurcuoglu, Gamze Karakurt, Ozge O Kaya, Gulden Diniz, Ozgür K?rb?y?k, Aysen Evkan, Enver Yaln |
| T790M and Acquired Resistance of Epidermal Growth Factor Receptor to Tyrosine Kinase Inhibitors in Patients with Lung Adenocarcinoma. Tanaffos 2023 4 21 (3): 376-383. Mirtavoos-Mahyari Hanifeh, Abbasi Dezfouli Azizollah, Esfahani-Monfared Zahra, Khosravi Adnan, Seifi Sharareh, Sheikhy Kamb |
| Distribution and prognostic impact of EGFR and KRAS mutations according to histological subtype and tumor invasion status in pTis-3N0M0 lung adenocarcinoma. BMC cancer 2023 3 23 (1): 248. Ito Masaoki, Miyata Yoshihiro, Kushitani Kei, Ueda Daisuke, Takeshima Yukio, Okada Morihi |
| Almonertinib Combined with Anlotinib and Temozolomide in a Patient with Recurrent Glioblastoma with EGFR L858R Mutation. The oncologist 2023 3 . Hou Zhiwei, Wu Huaguo, Luo Ningning, Li Shuo, Zhang Xiang, Dong Shuai, Zhu Dongyuan, Zhang Hui, Tao Rongj |
| Risk Factors for Recurrence of Stage I Epidermal Growth Factor Receptor Mutated Lung Adenocarcinoma. The Annals of thoracic surgery 2023 2 . Kamigaichi Atsushi, Mimae Takahiro, Tsubokawa Norifumi, Miyata Yoshihiro, Adachi Hiroyuki, Shimada Yoshihisa, Ito Hiroyuki, Ikeda Norihiko, Okada Morihi |
| Different prognostic role of EGFR mutation according to the IASLC histologic grade in patients with resected early-stage lung adenocarcinoma. Histopathology 2023 2 . Hong Tae Hee, Hwang Soohyun, Choi Yoon-La, Lee Genehee, Park Sehhoon, Ahn Myung-Ju, Lee Yoonseo, Jeon Yeong Jeong, Lee Junghee, Shin Sumin, Park Seong Yong, Cho Jong Ho, Choi Yong Soo, Kim Jhingook, Shim Young Mog, Cho Juhee, Kim Hong Kw |
| Efficacy of adjuvant chemotherapy in stage II/III NSCLC with EGFR mutation. The Thoracic and cardiovascular surgeon 2023 2 . Matsunaga Takeshi, Takamochi Kazuya, Hattori Aritoshi, Fukui Mariko, Suzuki Ken |
| ROS1 as a possible prognostic biomarker of cervical adenocarcinoma: An exploratory analysis with next-generation sequencing. Gynecologic oncology 2023 2 171 59-66. Machida Hiroko, Matsuo Koji, Tanaka Masayuki, Kitatani Kanae, Takase Akinori, Yokoyama Keiko, Kajiwara Hiroshi, Yasaka Miwa, Ikeda Masae, Yoshida Hiroshi, Hirasawa Takeshi, Mikami Mik |
| Clinicogenomic Landscape of Metastatic Thymic Epithelial Tumors. JCO precision oncology 2023 2 7 e2200465. Ardeshir-Larijani Fatemeh, Schneider Bryan P, Althouse Sandra K, Radovich Milan, Masood Ashiq, Perna Fabiana, Salman Huda, Loehrer Patrick |
| [Correlation Analysis of Ki67 Expression and EGFR Mutation on the Risk of Recurrence and Metastasis in Postoperative Patients with Stage I Lung Adenocarcinoma]. Zhongguo fei ai za zhi = Chinese journal of lung cancer 2023 1 25 (12): 852-861. Xu Lili, Guo Renh |
| Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2023 1 JCO2202186. Herbst Roy S, Wu Yi-Long, John Thomas, Grohe Christian, Majem Margarita, Wang Jie, Kato Terufumi, Goldman Jonathan W, Laktionov Konstantin, Kim Sang-We, Yu Chong-Jen, Vu Huu Vinh, Lu Shun, Lee Kye Young, Mukhametshina Guzel, Akewanlop Charuwan, de Marinis Filippo, Bonanno Laura, Domine Manuel, Shepherd Frances A, Urban Damien, Huang Xiangning, Bolanos Ana, Stachowiak Marta, Tsuboi Masahi |
| Clinical characteristics and prognostic value of EGFR mutation in stage I lung adenocarcinoma with spread through air spaces after surgical resection. Neoplasma 2023 1 69 (6): 1480-1489. Gao Mao-Gang, Wang Shi-Ze, Han Kai-Hong, Xie Shao-Nan, Liu Qing- |
- Page last reviewed:Feb 1, 2023
- Page last updated:May 22, 2023
- Content source: